- Home
- RYTM
as 02-21-2025 4:00pm EST
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Upcoming Earnings Alert:
Get ready for potential market movements as Rhythm Pharmaceuticals Inc. RYTM prepares to release earnings report on 26 Feb 2025.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 3.5B | IPO Year: | 2017 |
| Target Price: | $66.90 | AVG Volume (30 days): | 380.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.17 - $68.58 | Next Earning Date: | 02-26-2025 |
| Revenue: | $112,530,000 | Revenue Growth: | 81.55% |
| Revenue Growth (this year): | 66.58% | Revenue Growth (next year): | 44.63% |
Stock Insider Trading Activity of Rhythm Pharmaceuticals Inc. (RYTM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 12 '25 | Sell | $56.31 | 751 | $42,346.85 | 105,544 | |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 12 '25 | Sell | $56.74 | 469 | $26,451.81 | 5,619 | |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 9 '25 | Sell | $57.52 | 1,296 | $74,533.06 | 105,544 | |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Feb 9 '25 | Sell | $58.19 | 5,216 | $305,845.83 | 5,417 | |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 9 '25 | Sell | $57.51 | 791 | $45,490.41 | 5,619 | |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Feb 5 '25 | Sell | $61.02 | 3,066 | $185,640.20 | 5,417 | |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 1 '25 | Sell | $59.43 | 1,678 | $99,723.54 | 105,544 | |
| Lee Jennifer Kayden | RYTM | EVP, Head of North America | Feb 1 '25 | Sell | $59.43 | 1,447 | $85,995.21 | 5,417 | |
| Shulman Joseph | RYTM | Chief Technical Officer | Feb 1 '25 | Sell | $59.43 | 1,281 | $76,129.83 | 5,619 | |
| Meeker David P | RYTM | President and CEO | Feb 1 '25 | Sell | $59.43 | 4,278 | $254,241.54 | 189,927 |
Latest Rhythm Pharmaceuticals Inc. News
RYTM Breaking Stock News: Dive into RYTM Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
GlobeNewswire
9 days ago
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025
GlobeNewswire
17 days ago
Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February
Zacks
25 days ago
Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet
Simply Wall St.
a month ago
Exploring High Growth Tech Stocks in January 2025
Zacks
a month ago
Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock?
GlobeNewswire
a month ago
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
TipRanks
2 months ago
Jefferies starts Rhythm Pharmaceuticals with Buy on obesity potential
Compare RYTM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RYTM Rhythm Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.